BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite being a therapeutic area with high unmet need and a rich development pipeline, the barriers to market access for oncology therapies continue to rise. According to findings from the Strategic Insights report entitled Market Access Levers and Barriers: Maximizing the Opportunity for Key Oncology Agents, payer influence continues to grow as healthcare systems face escalating costs and diminishing resources to pay. As a therapy area with numerous high-cost targeted therapies, oncology drugs are a key target for controlling and reducing healthcare spend.
The findings also reveal a deep pipeline of agents in development for oncology; Decision Resources forecasts the launch of new targeted oncology drugs by 2019: a mix of small-molecule targeted therapies and targeted biologic agents. Given the depth of the targeted pipeline, and the increasingly cost-constrained environment, demonstrating innovation and proving value will be critical for obtaining favorable market access.
"Therapeutic innovation, improved target specificity and demonstrated downstream value are key market access levers that will encourage payers to think beyond the drug's price tag," said Decision Resources Senior Vice President, Research Kate Hohenberg. "In particular, factors that improve specificity such as personalized medicine, biomarkers and targeted patient populations increase the odds that a targeted therapy will work for a specific patient. And, value is derived from improved clinical effectiveness and later-line cost savings."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and
|SOURCE Decision Resources|
Copyright©2012 PR Newswire.
All rights reserved